choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:

Lymphoma Drugs Newsletter
  • Immunotherapy drug improves outcomes in high-risk blood cancer 19 Jun 2025 05:59 GMT

    … and efficacy of adding the drug glofitamab to each of these … cured by conventional treatments,” says Dr Adrian Minson, a lymphoma specialist at … a common chemotherapy-based treatment that includes five drugs: rituximab, cyclophosphamide, doxorubicin …

  • Can Tumor Patterns Predict Lymphoma Treatment Success? 19 Jun 2025 07:18 GMT

    … and stereotypical patterns in lymphoma microenvironment archetype profiles. Analysis … -occurred in three distinct lymphoma microenvironment archetype profiles characterized … first-line rituximab plus chemotherapy treatment. Analysis revealed that patients …

  • Tafasitamab Combo Approved for r/r Follicular Lymphoma 19 Jun 2025 06:11 GMT

    The US Food and Drug Administration has approved tafasitamab … therapies,” Khushali Jhaveri, MD, lymphoma specialist at Indiana University in … of the number of prior treatment lines patients had.  A … $1500.12, according to drugs.com. Incyte offers financial …

  • Johnson & Johnson Study Shows Promise for the Treatment and Potential Cure of Multiple Myeloma 19 Jun 2025 03:58 GMT

    … classes of treatment for multiple myeloma, namely immunomodulatory imide drugs (IMiDs), … for a one-time treatment.[17]  And treatment with CARVYKTI® can be … Mikhael, Treatment Options for Triple-class Refractory Multiple Myeloma, 20 Clin. Lymphoma Myeloma …

  • FDA Approves Tafasitamab in R/R Follicular Lymphoma 19 Jun 2025 04:13 GMT

    … administered via intravenous infusion. Treatment is intended for up … 47;refractory marginal zone lymphoma and is not recommended … relapsed or refractory follicular lymphoma. News release. US FDA … relapsed or refractory follicular lymphoma: results from a phase …

  • Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma 19 Jun 2025 03:24 GMT

    … lenalidomide for the treatment of relapsed or refractory follicular lymphoma, providing a … ;refractory follicular lymphoma] were very limited. However, with newer treatments such as …

  • FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma 19 Jun 2025 01:44 GMT

    … a treatment for patients with relapsed or refractory follicular lymphoma, … or refractory follicular lymphoma were randomly assigned … the treatment of relapsed or refractory marginal zone lymphoma … relapsed or refractory follicular lymphoma. FDA. June 18, …

  • FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma 19 Jun 2025 01:08 GMT

    … .S. Food and Drug Administration (FDA) approved treatment with Monjuvi (tafasitamab-cxix … with relapsed or refractory follicular lymphoma. The effectiveness of Monjuvi was … up the review of cancer drugs by working with regulatory agencies …

  • Gene Hunt Leads to Potential Colorectal Cancer Treatment, Stanley J. Glaser Award 19 Jun 2025 00:57 GMT

    … combination with the chemotherapy drug irinotecan, a current treatment for colorectal cancer … mutations associated with leukemia and lymphoma. They zeroed in on XPO1 … combination of selinexor with immunotherapy drugs and to investigate whether XPO1R749Q …

  • FDA Approves Tafasitamab Combo for R/R Follicular Lymphoma 19 Jun 2025 00:29 GMT

    … and the most common treatment-emergent adverse effects (TEAEs … clinical trials for that treatment.1,2 Patients … for relapsed or refractory follicular lymphoma. FDA. June 18, … drugs/fda-approves-tafasitamab-cxix-relapsed-or-refractory-follicular-lymphoma …

Satisfied with the content?

Continue to create your account.